Ladenburg Thalmann Initiates Coverage on Trillium Therapeutics to Buy

Ladenburg Thalmann Initiates Coverage on Trillium Therapeutics(NASDAQ:TRIL). The shares have been rated Buy. The rating by Ladenburg Thalmann was issued on Aug 3, 2016.

Trillium Therapeutics (TRIL) made into the market gainers list on Fridays trading session with the shares advancing 2.39% or 0.24 points. Due to strong positive momentum, the stock ended at $10.29, which is also near the day’s high of $10.37. The stock began the session at $10.16 and the volume stood at 25,031 shares. The 52-week high of the shares is $20.19 and the 52 week low is $6.62. The company has a current market capitalization of $80 M and it has 78,14,883 shares in outstanding.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Trillium Therapeutics - Is it time to Sell?

Top Brokerage Firms are advising their investors on Trillium Therapeutics. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.